Literature DB >> 14705869

Clinical relevance of P-glycoprotein in drug therapy.

Jiunn H Lin1, Masayo Yamazaki.   

Abstract

The drug efflux transporter P-glycoprotein (P-gp) is known to confer multidrug resistance in cancer chemotherapy. The P-gp is highly expressed in many types of tumor cells, as well as many normal tissues, including the apical surface of intestinal epithelial cells, and the luminal surface of capillary endothelial cells in the brain. Because of its expression and localization, it has been suggested that P-gp plays an important role in cancer chemotherapy, intestinal absorption, and brain uptake. This review addresses the significance of the role of P-gp in cancer chemotherapy, drug absorption, and brain uptake. Based on the clinical and animal studies with P-gp modulators, it has become apparent that the role of P-gp in multidrug resistance is far less important compared to other biological factors. Although P-gp is highly expressed in both intestinal epithelial cells and endothelial cells of brain capillaries and functions as an efflux transporter in both organs, the magnitude of P-gp's impact on intestinal absorption and brain uptake of drugs is quantitatively very different. From animal and clinical studies, it is evident that P-gp plays a very important role in CNS penetration of drugs, whereas the effect of P-gp on drug absorption is not as important as generally believed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14705869     DOI: 10.1081/dmr-120026871

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  30 in total

1.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

2.  The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.

Authors:  Jack G Shi; Yan Zhang; Swamy Yeleswaram
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

3.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 4.  Efflux transporters as a novel herbivore countermechanism to plant chemical defenses.

Authors:  Jennifer S Sorensen; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

Review 5.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

7.  A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions.

Authors:  Matthew H Crouthamel; Daniel Wu; Ziping Yang; Rodney J Y Ho
Journal:  AAPS J       Date:  2010-07-10       Impact factor: 4.009

8.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

9.  Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Authors:  Matthew L Rizk; Robert Houle; Grace Hoyee Chan; Mike Hafey; Elizabeth G Rhee; Xiaoyan Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Authors:  Birk Poller; Jürgen Drewe; Stephan Krähenbühl; Jörg Huwyler; Heike Gutmann
Journal:  Cell Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.